Surface Proteomics Reveals CD72 as a Target for <i>In Vitro</i>–Evolved Nanobody-Based CAR-T Cells in <i>KMT2A/MLL1</i>-Rearranged B-ALL

  • Matthew A. Nix
    1Department of Laboratory Medicine, University of California, San Francisco, San Francisco, California.
  • Kamal Mandal
    1Department of Laboratory Medicine, University of California, San Francisco, San Francisco, California.
  • Huimin Geng
    1Department of Laboratory Medicine, University of California, San Francisco, San Francisco, California.
  • Neha Paranjape
    1Department of Laboratory Medicine, University of California, San Francisco, San Francisco, California.
  • Yu-Hsiu T. Lin
    1Department of Laboratory Medicine, University of California, San Francisco, San Francisco, California.
  • Jose M. Rivera
    2Department of Pediatrics, University of California, San Francisco, San Francisco, California.
  • Makeba Marcoulis
    1Department of Laboratory Medicine, University of California, San Francisco, San Francisco, California.
  • Kristie L. White
    1Department of Laboratory Medicine, University of California, San Francisco, San Francisco, California.
  • Jeffrey D. Whitman
    1Department of Laboratory Medicine, University of California, San Francisco, San Francisco, California.
  • Sagar P. Bapat
    1Department of Laboratory Medicine, University of California, San Francisco, San Francisco, California.
  • Kevin R. Parker
    3Department of Pathology, Stanford University, Stanford, California.
  • Jonathan Ramirez
    4Cardiovascular Research Institute, University of California, San Francisco, San Francisco, California.
  • Anne Deucher
    1Department of Laboratory Medicine, University of California, San Francisco, San Francisco, California.
  • Paul Phojanokong
    5Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, California.
  • Veronica Steri
    5Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, California.
  • Faranak Fattahi
    4Cardiovascular Research Institute, University of California, San Francisco, San Francisco, California.
  • Byron C. Hann
    5Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, California.
  • Ansuman T. Satpathy
    3Department of Pathology, Stanford University, Stanford, California.
  • Aashish Manglik
    6Department of Pharmaceutical Chemistry, University of California, San Francisco, San Francisco, California.
  • Elliot Stieglitz
    2Department of Pediatrics, University of California, San Francisco, San Francisco, California.
  • Arun P. Wiita
    1Department of Laboratory Medicine, University of California, San Francisco, San Francisco, California.

この論文をさがす

説明

<jats:title>Abstract</jats:title> <jats:sec> <jats:title/> <jats:p>Alternative strategies are needed for patients with B-cell malignancy relapsing after CD19-targeted immunotherapy. Here, cell surface proteomics revealed CD72 as an optimal target for poor-prognosis KMT2A/MLL1-rearranged (MLLr) B-cell acute lymphoblastic leukemia (B-ALL), which we further found to be expressed in other B-cell malignancies. Using a recently described, fully in vitro system, we selected synthetic CD72-specific nanobodies, incorporated them into chimeric antigen receptors (CAR), and demonstrated robust activity against B-cell malignancy models, including CD19 loss. Taking advantage of the role of CD72 in inhibiting B-cell receptor signaling, we found that SHIP1 inhibition increased CD72 surface density. We establish that CD72-nanobody CAR-T cells are a promising therapy for MLLr B-ALL.</jats:p> </jats:sec> <jats:sec> <jats:title>Significance:</jats:title> <jats:p>Patients with MLLr B-ALL have poor prognoses despite recent immunotherapy advances. Here, surface proteomics identifies CD72 as being enriched on MLLr B-ALL but also widely expressed across B-cell cancers. We show that a recently described, fully in vitro nanobody platform generates binders highly active in CAR-T cells and demonstrate its broad applicability for immunotherapy development.</jats:p> <jats:p>This article is highlighted in the In This Issue feature, p. 1861</jats:p> </jats:sec>

収録刊行物

  • Cancer Discovery

    Cancer Discovery 11 (8), 2032-2049, 2021-05-16

    American Association for Cancer Research (AACR)

被引用文献 (1)*注記

もっと見る

詳細情報 詳細情報について

問題の指摘

ページトップへ